Botanix Pharmaceuticals Ltd has released a press release.
Botanix Commences BTX 1204 Dermatitis Patient Study
Filed with ASX ·
Watch Botanix Pharmaceuticals' latest callBotanix Pharmaceuticals (ASX:BOT) Q2 2026 Earnings Call · Replay · Mar 2Read the transcript of Botanix Pharmaceuticals (ASX:BOT) Q2 2026 Earnings Call6ix hasn’t read this filing yet.
Botanix Pharmaceuticals Limited on 6ix
Earlier from Botanix Pharmaceuticals
- FDA Clears Development Path for BTX 1503
- Botanix Commences BTX 1503 Acne Patient Study
- Botanix Completes Successful Phase 1 BTX 1503 Clinical Study
- 12 Month Operational Review Highlights Significant Progress
- Successful Pilot Study for BTX 1701 Facial Cleanser
Later from Botanix Pharmaceuticals
- Botanix Enrols First Patients in Dermatitis Study
- New Antibacterial Results Support BTX 1503 Acne Program
- Botanix Completes Enrolment of BTX 1503 Acne Patient Study
- Botanix Receives A$1.6m R&D Tax Incentive Refund
- Botanix Announces Successful Acne Study Results
Follow Botanix Pharmaceuticals into a list and get an email when it puts out news.
Follow Botanix Pharmaceuticals